With the objective of evaluating the effect of FE and HFE on CRC cancer metabolism and risk factors related to obesity and inflammation, we designed a panel of metabolic genes—including de novo lipogenesis and cholesterogenesis (SREBF1, FASN; SCD; SREBF2, HMGCR), fatty acid metabolism (ACSL1, ACSL4, SCD), oncogenic pathways in CRC (CHOKA, BMP2), exogenous uptake of lipids (LDLR, FABP1), cholesterol metabolism (ABCA1, ApoA1), inflammation and oxidative stress (JAK1, NEF2L2), and resistance to chemotherapy (TK1, TYMS). This evidence concerns the gene ACSL4 and cancer.